Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion.
Alefacept is a chimeric protein combining CD58 immunoglobulin-like domain 1 with human IgG1 Fc. Alefacept mediates adhesion by bridging CD2 on T cells to activating Fc receptors on effector cells, but the equilibrium binding parameters have not been determined. Alefacept mediated T cell killing by N...
Main Authors: | Dustin, M, Starr, T, Coombs, D, Majeau, G, Meier, W, Hochman, P, Douglass, A, Vale, R, Goldstein, B, Whitty, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2007
|
Similar Items
-
Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes
by: Elisa Balmas, et al.
Published: (2023-11-01) -
A model for CD2/CD58-mediated adhesion strengthening.
by: Shao, J, et al.
Published: (2005) -
The CD58-CD2 axis in cancer immune evasion
by: Quastel, M, et al.
Published: (2022) -
Mechanisms of Cellular Avidity Regulation in CD2-CD58-Mediated T Cell Adhesion.
by: Zhu, D, et al.
Published: (2006) -
Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects
by: Kirsten E. Diggins, et al.
Published: (2021-02-01)